Lupus medication typically starts with an antimalarial drug called hydroxychloroquine, which is recommended for nearly every person diagnosed with systemic lupus erythematosus (SLE). From there, treatment is layered based on how severe the disease is and which organs are affected. The medications range from anti-inflammatory steroids to powerful immune-suppressing drugs and newer biologic therapies, each targeting a different part of the overactive immune response that drives lupus.
Hydroxychloroquine: The Foundation of Lupus Treatment
Hydroxychloroquine (brand name Plaquenil) is the closest thing lupus treatment has to a universal medication. Current guidelines from the European League Against Rheumatism recommend it for all lupus patients unless there’s a specific reason they can’t take it. The standard dose is up to 5 mg per kilogram of body weight per day, with a maximum of 400 mg daily.
The drug works by slipping into immune cells and disrupting their internal recycling machinery. Normally, certain compartments inside immune cells break down proteins and present them to the rest of the immune system, sometimes triggering an attack against the body’s own tissues. Hydroxychloroquine raises the acidity level inside these compartments, essentially gumming up the works. This reduces the production of inflammatory signals and helps quiet the immune system’s mistaken assault on healthy tissue.
Most people tolerate hydroxychloroquine well for years, but it does carry a risk of retinal damage with long-term use. You should have a baseline eye exam within the first year of starting the drug. If you’re on the recommended dose, annual eye screenings aren’t necessary until you’ve been on it for five years. After that, yearly screening catches any early retinal changes before they affect vision. People with kidney disease or significant weight loss may need more frequent checks.
Corticosteroids for Flare Control
When hydroxychloroquine alone isn’t enough to control symptoms, corticosteroids like prednisone are often added. These drugs are powerful, fast-acting anti-inflammatory agents that can tamp down a lupus flare within days. The dose depends entirely on what’s happening in the body. For severe flares involving the kidneys or nervous system, doctors may start with 1 mg per kilogram of body weight per day for two to four weeks, then gradually taper down. In very serious situations, high-dose pulses given intravenously over one to three days can bring intense inflammation under control quickly.
The goal with steroids is always to use them at the lowest effective dose for the shortest time possible. Guidelines recommend tapering to no more than 5 mg of prednisone per day for ongoing use, and ideally stopping them altogether. Long-term steroid use at higher doses raises the risk of bone thinning, weight gain, high blood sugar, infections, and mood changes. Much of lupus treatment strategy revolves around finding other medications that allow you to reduce or eliminate steroids.
Immunosuppressants for Organ Involvement
When lupus affects major organs like the kidneys, lungs, brain, or cardiovascular system, stronger medications that suppress the immune system more broadly become necessary. These are also used when someone can’t taper their steroid dose low enough without flaring. The most commonly used options include methotrexate, azathioprine, and mycophenolate, each suited to slightly different situations.
Methotrexate is often used for joint and skin symptoms that don’t respond to hydroxychloroquine. Azathioprine serves as a maintenance option after more aggressive initial treatment and has a long track record. Mycophenolate is particularly important for lupus nephritis, the kidney inflammation that develops in a significant number of lupus patients. For the most severe kidney disease or life-threatening situations, cyclophosphamide, a more potent immunosuppressive, may be used when other options have failed.
All immunosuppressants work by broadly dialing down immune activity, which means they increase susceptibility to infections. Regular blood work is standard while on these medications to monitor immune cell counts, liver function, and kidney function. The tradeoff is straightforward: the risk of infection and other side effects is weighed against the risk of letting lupus damage vital organs.
Biologic Therapies
Two biologic medications are now FDA-approved specifically for lupus, offering more targeted immune suppression than traditional immunosuppressants. Belimumab (Benlysta), approved in 2011, works by blocking a protein that helps certain immune cells survive and multiply. It’s available as an intravenous infusion given every four weeks (after initial loading doses) or as a weekly self-injection. Anifrolumab (Saphnelo), approved in 2021, targets a different pathway tied to the type of immune signaling that’s overactive in many lupus patients. It’s given as an intravenous infusion every four weeks.
These biologics are typically added on top of existing treatment rather than replacing it. Guidelines position them alongside traditional immunosuppressants as options for people who aren’t responding adequately to hydroxychloroquine and steroids alone. Belimumab has also shown benefit specifically in lupus nephritis when combined with standard kidney-directed therapy.
Rituximab, a biologic originally developed for certain cancers and approved for other autoimmune conditions, is used off-label for refractory lupus. Both European and American guidelines recommend it for lupus nephritis that hasn’t responded to standard treatment. Studies suggest it provides meaningful benefit in severe or treatment-resistant cases, though two controlled trials failed to meet their primary goals when rituximab was added to conventional therapy. Despite this, it remains a widely accepted option for the toughest cases. Roughly 0.5% to 1.5% of lupus patients in Europe receive it off-label.
Treating Lupus Nephritis Specifically
Kidney involvement deserves special mention because it’s one of the most serious complications of lupus and has its own treatment pathway. Active proliferative lupus nephritis is typically treated with either low-dose cyclophosphamide or mycophenolate, combined with steroid pulses followed by lower oral doses. The newer drug voclosporin (Lupkynis), taken orally twice daily, was specifically developed for lupus nephritis and is used alongside mycophenolate. It works by calming the immune cells that drive kidney inflammation.
The combination approach, using belimumab or a calcineurin inhibitor like voclosporin alongside mycophenolate, represents the current direction of lupus nephritis treatment. The goal is to protect kidney function and achieve a measurable response: normalized protein levels in urine and stable kidney filtration rates.
Pregnancy and Lupus Medications
Pregnancy planning is a critical consideration because some lupus medications are safe to continue and others must be stopped well in advance. Hydroxychloroquine is not only safe during pregnancy but recommended, since stopping it raises the risk of flares. Azathioprine has been used extensively in pregnant patients with no reported birth defects. Low-dose prednisone can be continued at the lowest effective dose, though higher doses increase obstetrical risks.
Methotrexate must be stopped one to three months before attempting pregnancy. Mycophenolate needs to be discontinued at least six weeks beforehand. Both carry known risks of birth defects. NSAIDs should generally be avoided during pregnancy, especially in the third trimester, and COX-2 inhibitors and full-dose aspirin are off the table entirely. Low-dose aspirin, however, is actually recommended starting at 12 weeks to reduce the risk of preeclampsia, which lupus patients face at higher rates.
How Treatment Is Layered Over Time
Lupus treatment follows a clear escalation pattern. Nearly everyone starts with hydroxychloroquine. If that’s not enough, low-dose steroids are added to control flares, with the constant goal of tapering them as quickly as possible. When steroids can’t be reduced or organs are at risk, immunosuppressants or biologics enter the picture. For life-threatening disease, the most powerful agents like cyclophosphamide are brought in, with rituximab held in reserve for cases that resist everything else.
The overarching goals are remission or, when that’s not achievable, the lowest possible disease activity. Early diagnosis, prompt treatment, and consistent medication adherence are the strongest predictors of long-term outcomes. Skipping doses of hydroxychloroquine, for instance, measurably increases flare risk. Because lupus is a chronic condition that waxes and wanes, most people will be on some form of medication long-term, with the specific combination adjusted as their disease evolves.